CSPC Pharma's siRNA drug SYH2068 receives clinical trial approval

CSPC Pharmaceutical Group Limited (HKEX:1093) announced that its SYH2068 injection, a double-stranded small interfering RNA (siRNA) drug, has received clinical trial approval from the National Medical Products Administration of the People's Republic of China. SYH2068, classified as a Class 1 new chemical drug, is designed for liver-targeted delivery to reduce lipoprotein(a) [Lp(a)] levels, a key factor in atherosclerotic cardiovascular disease (ASCVD). Preclinical studies demonstrated that the drug exhibits superior pharmacological activity and a longer duration of efficacy compared to similar siRNA products, with a good safety profile. The company anticipates that SYH2068 will become an ultra-long-acting siRNA drug for Lp(a) reduction.